CN Bio

CN Bio is a pioneer and commercial leader in the Organ-on-a-Chip (OOC) field, founded in 2009 and based in Cambridge, UK. Its core offering is the PhysioMimix platform, an integrated microphysiological system designed to generate human-relevant data for drug discovery, aiming to reduce reliance on animal models. The company operates a hybrid business model, selling its systems and consumables while also providing fee-for-service studies, and boasts adoption by 16 of the top 20 pharmaceutical companies. CN Bio is positioned at the intersection of the global push for New Approach Methodologies (NAMs) and the growing demand for more predictive, human-specific preclinical data.

PhysioMimix platform: an integrated suite of benchtop microphysiological systems (hardware), multi-chip plates, 3D validated human cells, and assay protocols to create functional human Organ-on-a-Chip models (e.g., liver, lung, gut/liver) for predictive drug testing.

CN Bio competes in the growing Organ-on-a-Chip market against other specialized players like Emulate, Inc. and Mimetas, as well as academic groups developing similar technologies. Its key competitive differentiators appear to be its focus on user-friendly, integrated systems (PhysioMimix Core), validated multi-organ models, and its established adoption by a majority of top pharmaceutical companies.